Fluoxetine Disposition in Patients with Chronic Hepatitis C Treated with Interferon-α

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2010 Oct 7

PMID 20923249

Citations 3

Authors

Mario Furlanut

Giorgio Soardo

Debora Donnini

Leonardo Sechi

Loretta Franceschi

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Combination therapy with interferon-α and ribavirin is considered the treatment of choice for chronic hepatitis C. However, interferon-α may induce severe depression. It has been suggested that interferon-α is able to modify cytochrome P450 (CYP) 1A2 and 2D6 activity. We therefore decided to study the effects of the interferon-α-2b pegylated derivative on fluoxetine disposition in patients receiving combination chemotherapy for chronic hepatitis C.

Methods: After approval by the institutional ethics committee, 20 adult patients with chronic hepatitis C, but with no history of other liver diseases, were prospectively admitted to the study, which included phenotyping by means of a dextromethorphan test and evaluation of fluoxetine and norfluoxetine pharmacokinetic parameters (the area under the serum concentration-time curve, maximum serum concentration, time to reach the maximum serum concentration and terminal elimination half-life) before and after 2 months of continuous peginterferon-α-2b therapy.

Results: The only statistically significant difference we observed was a significant reduction in the terminal elimination half-life of fluoxetine (from 47.30 to 33.23 hours; p = 0.014) after peginterferon-α-2b treatment.

Conclusion: These data suggest that interferon-α may induce, rather than inhibit, the biotransformation of fluoxetine.

Citing Articles

Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature.

Lenoir C, Rollason V, Desmeules J, Samer C Front Pharmacol. 2021; 12:733935.

PMID: 34867341 PMC: 8637893. DOI: 10.3389/fphar.2021.733935.

Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment.

Schmidt F, Kirkby K, Lichtblau N Curr Neuropharmacol. 2016; 14(7):674-87.

PMID: 26769225 PMC: 5050395. DOI: 10.2174/1570159x14666160115130414.

Fluoxetine is a potent inhibitor of coxsackievirus replication.

Zuo J, Quinn K, Kye S, Cooper P, Damoiseaux R, Krogstad P Antimicrob Agents Chemother. 2012; 56(9):4838-44.

PMID: 22751539 PMC: 3421851. DOI: 10.1128/AAC.00983-12.

References

Wong S, Dellafera S, Fernandes R, Kranzler H . Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. J Chromatogr. 1990; 499:601-8. DOI: 10.1016/s0021-9673(00)97004-3. View

RENAULT P, Hoofnagle J, Park Y, Mullen K, Peters M, Jones D . Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med. 1987; 147(9):1577-80. View

Kraus M, Schafer A, Faller H, Csef H, Scheurlen M . Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther. 2002; 16(6):1091-9. DOI: 10.1046/j.1365-2036.2002.01265.x. View

Musselman D, Lawson D, Gumnick J, Manatunga A, Penna S, Goodkin R . Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344(13):961-6. DOI: 10.1056/NEJM200103293441303. View

Islam M, Frye R, Richards T, Sbeitan I, Donnelly S, Glue P . Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res. 2002; 8(8):2480-7. View

Levenson J, FALLON H . Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol. 1993; 88(5):760-1. View

Shibata T, Shimada Y, Shimoyama M . Time-dependent cytotoxic action of human recombinant alpha-interferon (Ro22-8181) in vitro and the sensitivity of various cultured leukemia and lymphoma cell lines to it. Jpn J Clin Oncol. 1985; 15(1):67-75. View

McHutchison J, Gordon S, Schiff E, Shiffman M, Lee W, Rustgi V . Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339(21):1485-92. DOI: 10.1056/NEJM199811193392101. View

Hildebrand M, Seifert W, Reichenberger A . Determination of dextromethorphan metabolizer phenotype in healthy volunteers. Eur J Clin Pharmacol. 1989; 36(3):315-8. DOI: 10.1007/BF00558166. View

10.

Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View

11.

Abe S, Hori T, Suzuki T, Baba A, Shiraishi H, Yamamoto T . Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res. 1999; 24(3):359-63. DOI: 10.1023/a:1020929415443. View

12.

Becquemont L, Chazouilleres O, Serfaty L, Poirier J, Broly F, Jaillon P . Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther. 2002; 71(6):488-95. DOI: 10.1067/mcp.2002.124468. View

13.

Fried M, Shiffman M, Reddy K, Smith C, Marinos G, Goncales Jr F . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347(13):975-82. DOI: 10.1056/NEJMoa020047. View

14.

Neri S, Pulvirenti D, Bertino G . Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig. 2006; 26(11):655-62. DOI: 10.2165/00044011-200626110-00005. View

15.

Strader D, Wright T, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4):1147-71. DOI: 10.1002/hep.20119. View

16.

Kraus M, Schafer A, Faller H, Csef H, Scheurlen M . Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003; 64(6):708-14. DOI: 10.4088/jcp.v64n0614. View

17.

Cheer S, Goa K . Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs. 2001; 61(1):81-110. DOI: 10.2165/00003495-200161010-00010. View

18.

Hamelin B, Turgeon J, Vallee F, BELANGER P, Paquet F, Lebel M . The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther. 1996; 60(5):512-21. DOI: 10.1016/S0009-9236(96)90147-2. View

19.

Reddy K . Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother. 2000; 34(7-8):915-23. DOI: 10.1345/aph.10054. View

20.

Schenker S, Bergstrom R, Wolen R, Lemberger L . Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1988; 44(3):353-9. DOI: 10.1038/clpt.1988.161. View